

Ad-hoc release pursuant to § 15 Wertpapierhandelsgesetz (German Securities Trading Act)

REDECTANE[®] meets both endpoints specificity and sensitivity with superiority over CT in its pivotal Phase III trial

Munich, 18 May 2010. WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) announced today that the final results of the pivotal phase III registration trial REDECT have been received. The results of the study demonstrate that PET/CT with REDECTANE[®] lead to a significantly improved diagnosis in comparison to CT alone.

The aim of the Phase III-REDECT study was to determine whether the combination of REDECTANE[®] with positron emission tomography (PET) and computer tomography (CT) versus the standard use of CT alone could improve the diagnosis of renal masses. Sensitivity and specificity were the defined endpoints of the study.

In contrast to the preliminary data published in November 2009, the endpoint sensitivity, the correct diagnosis that clear cell renal cell cancer is present, was reached with statistical significance (p value, p) ($p \leq 0.016$) compared to CT. The study endpoint specificity, the correct diagnosis that clear cell renal cell cancer is not present, was confirmed with a highly statistical significance ($p < 0.001$). To rule out that the superiority of REDECTANE[®] resulted from the poor performance of CT, the endpoints of REDECTANE[®] were also compared to an arbitrary value of 75% for specificity and sensitivity as defined in the study protocol. REDECTANE[®] achieved sensitivity of 86% ($p \leq 0.002$) and specificity of 87% ($p = 0.057$). Based on these results, WILEX plans to submit REDECTANE[®] for approval by the US Food and Drug Administration (FDA) at the end of 2010.

Further information will be published in a press release.

Contact

WILEX AG
Katja Arnold (CIRO)
Corporate Communications
Grillparzerstr. 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
Email: investors@wilex.com

This communication contains certain forward-looking statements, relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.